Navigation Links
Aimago Strengthens and Expands IP Portfolio
Date:8/26/2013

be used continuously, but it has the ability to visualize blood flow in large vessels and inner organs.

While the principle of ICG / fluorescent based perfusion imaging is in public domain, the now licensed patent applications seek to protect the combination of LDI with ICG / fluorescence imaging into one single imaging device. These patent applications, filed in 2007, are currently in review phases in both the United States and Germany.

Prof. Theo Lasser, head of the EPFL Biomedical Optics Lab and co-founder of Aïmago, has experience with ICG and comments: "We are satisfied to see that Aïmago now has access to the entire IP package. From a clinical perspective, the implemented LDI modality covers the majority of applications related to skin perfusion imaging, while ICG / fluorescence imaging opens the door to deeper tissues and organs – all through one single, highly intuitive instrument."

About Aïmago

Aïmago is a privately held, medical device company founded as a spin-off from EPFL in 2008. The tablet-inspired and FDA cleared Aïmago EasyLDI Perfusion Camera empowers clinicians and nurses to obtain clinically relevant, objective and repeatable insights into the perfusion reality. Emphasizing on usability, EasyLDI essentially works like a point-and-shoot camera: No injections, no turning-off the ambient light, no extra personnel, no waiting, and no limitations to use. The company has won several awards, including the CTI MedTech Award 2011 from the Swiss government and the W.A. de Vigier Award for best Swiss start-up. More information is available at www.aimago.com.

Media Contact: Michael Friedrich, Aïmago SA, +41215105560, michael.friedrich@aimago.co
'/>"/>

SOURCE Aïmago SA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Commercial Release of 3D (Breast Tomosynthesis) Biopsy Option Strengthens Hologics Position as Provider of the Nations Most Comprehensive Portfolio of Interventional Breast Health Solutions
2. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
3. Global Pharmaceutical Company Strengthens Compliance Using Vault PromoMats and Veeva CRM
4. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
5. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
6. Alliqua Strengthens and Realigns Executive Team
7. inVentiv Health Strengthens Clinical Leadership Team
8. Jardogs Strengthens Leadership Team with the Addition of Two Seasoned Healthcare Executives
9. Pharmalink AB Strengthens Senior Management Team
10. Actinium Pharmaceuticals Strengthens Management Team
11. PAREXEL Strengthens Outcomes Research Capabilities To Help Biopharma Meet Commercialization Goals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
... SiteJabber.com , a leading consumer protection service which helps people avoid fraudulent websites and find good sites, and LegitScript.com ... websites and avoid fraudulent ones. , ... ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 2SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 3
(Date:10/30/2014)... of data from an institutional patient registry on ... control, 79 percent of tumors, for medically inoperable, ... from 2003 to 2012, according to research presented ... Thoracic Oncology. The Symposium is sponsored by the ... Society for Radiation Oncology (ASTRO), the International Association ...
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Five months ... Hodgkinson Street LLC announces new branding and a ... Street Mepham . After David Mepham’s promotion to name ... brand and website to include Mepham’s name and better ... malpractice and mediation firm, the decision to implement new ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
... The Lupus Foundation of,America (LFA) is ... in grant funding,for basic, clinical, or translational ... fatal autoimmune disease. The purposes of the,studies ... novel,approaches; and develop experimental prototypes. Grants will ...
... Council (ACC) today sent a letter to FDA ... review of the safety of bisphenol A,in food ... study regarding bisphenol A is well,documented and well ... the safety and use of polycarbonate plastic and ...
... Mass., April 17 Inverness Medical,Innovations, Inc. (Amex: ... point-of-care,diagnostic products, today announced that it will release ... 2008. The Company will also host a,conference call ... date to,discuss these results and other corporate matters. ...
... They,re more disruptive than long hours, night shifts or job ... Common job-related problems such as conflicts with bosses or co-workers ... insecurity to cause poor sleep. , That,s the conclusion of ... from two surveys of about 2,300 U.S. adults who were ...
... Pennsylvania School of Medicine are developing a novel approach ... as amyotrophic lateral sclerosis (ALS), or Lou Gehrig,s disease, ... mutations have been found in a disease protein called ... of frontotemporal dementia (FTD). , We,ve created a ...
... KIRKLAND, Wash., April 17 For health reasons, Americans,in ... than they think,according to Denise Gott, Vice Chairperson of ... long term care insurance agencies.,"The sudden need for long ... "and they,re vulnerable on two fronts, not just one, ...
Cached Medicine News:Health News:Lupus Foundation of America Seeks Funding Proposals for Research Studies on Childhood Lupus, Nervous System Involvement, and More 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results 2Health News:Work Conflicts Can Do a Job on Your Sleep 2Health News:Penn researchers find potential in yeast for selecting Lou Gehrig's disease drugs 2Health News:Today's Working Adults Face Long Term Care 'Double Whammy,' Says Denise Gott, Spokesperson for LTC Financial Partners, LLC 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: